Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis

Keyphrases

• Meta-analysis 100%
• Plasmodium Vivax 100%
• Recurrence Risk 100%
• Primaquine 100%
• Individual Patient Data 100%
• P. Vivax 26%
• Tolerability 21%
• Daily Dose 21%
• Total Dose 21%
• Efficacy Analysis 15%
• Gastrointestinal Diseases 15%
• High Dose 10%
• Patient-level Data 10%
• Treatment Duration 5%
• Health Research 5%
• Treatment Group 5%
• Adjusted Hazard Ratio 5%
• Between-day 5%
• Medical Records 5%
• Artemisinin-based Combination Therapy 5%
• Chloroquine 5%
• Endemic Countries 5%
• Cochrane 5%
• Prospero 5%
• Embase 5%
• Medical Research Council 5%
• National Health 5%
• MEDLINE 5%
• Endemic Region 5%
• Risk of Bias 5%
• Artemether-lumefantrine 5%
• Bill & Melinda Gates Foundation 5%
• Web of Science 5%
• Vivax 5%
• Cox Proportional Hazards Regression 5%
• Active Follow-up 5%
• Dosing Regimen 5%
• Initial Infection 5%
• Modified Poisson Regression 5%
• Medicines for Malaria Venture 5%
• Severe Malaria 5%
• Prospective Clinical Study 5%
• Hypnozoite 5%
• Optimal Dosing Regimen 5%

Pharmacology, Toxicology and Pharmaceutical Science

• Recurrent Disease 100%
• Plasmodium vivax 100%
• Primaquine 100%
• Tolerability 21%
• Gastrointestinal Symptom 15%
• Malaria 10%
• Low Drug Dose 10%
• Infection 5%
• Combination Therapy 5%
• Clinical Study 5%
• Chloroquine 5%
• Artemisinin 5%
• Treatment Group 5%